SG Americas Securities LLC increased its holdings in shares of Illumina, Inc. (NASDAQ:ILMN) by 7.6% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 22,748 shares of the life sciences company’s stock after purchasing an additional 1,610 shares during the quarter. SG Americas Securities LLC’s holdings in Illumina were worth $6,920,000 at the end of the most recent reporting period.
Several other large investors have also modified their holdings of the stock. Cim Investment Mangement Inc. boosted its stake in shares of Illumina by 3.9% in the 2nd quarter. Cim Investment Mangement Inc. now owns 2,383 shares of the life sciences company’s stock valued at $877,000 after buying an additional 89 shares during the period. Copper Rock Capital Partners LLC purchased a new stake in Illumina during the second quarter worth approximately $10,888,000. Arjuna Capital purchased a new stake in Illumina during the second quarter worth approximately $269,000. Handelsbanken Fonder AB lifted its stake in Illumina by 45.6% during the second quarter. Handelsbanken Fonder AB now owns 60,653 shares of the life sciences company’s stock worth $22,329,000 after purchasing an additional 19,000 shares during the last quarter. Finally, Kornitzer Capital Management Inc. KS lifted its stake in Illumina by 20.4% during the third quarter. Kornitzer Capital Management Inc. KS now owns 104,845 shares of the life sciences company’s stock worth $31,896,000 after purchasing an additional 17,796 shares during the last quarter. 90.94% of the stock is owned by hedge funds and other institutional investors.
In other Illumina news, SVP Mostafa Ronaghi sold 10,000 shares of the firm’s stock in a transaction that occurred on Thursday, August 15th. The stock was sold at an average price of $285.52, for a total transaction of $2,855,200.00. Following the completion of the sale, the senior vice president now owns 86,585 shares in the company, valued at approximately $24,721,749.20. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, SVP Charles Dadswell sold 193 shares of the firm’s stock in a transaction that occurred on Friday, November 1st. The shares were sold at an average price of $297.28, for a total value of $57,375.04. Following the sale, the senior vice president now owns 5,069 shares of the company’s stock, valued at approximately $1,506,912.32. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 32,638 shares of company stock valued at $9,580,415. 0.38% of the stock is owned by insiders.
Shares of NASDAQ:ILMN traded down $1.86 during trading on Friday, reaching $293.39. The company had a trading volume of 935,600 shares, compared to its average volume of 1,040,401. The firm has a market capitalization of $44.23 billion, a price-to-earnings ratio of 51.29, a price-to-earnings-growth ratio of 2.22 and a beta of 1.03. The company has a debt-to-equity ratio of 0.41, a current ratio of 6.82 and a quick ratio of 6.15. The stock’s fifty day moving average price is $302.08 and its 200 day moving average price is $310.65. Illumina, Inc. has a fifty-two week low of $263.30 and a fifty-two week high of $380.76.
Illumina (NASDAQ:ILMN) last announced its quarterly earnings results on Thursday, October 24th. The life sciences company reported $1.93 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $1.40 by $0.53. Illumina had a return on equity of 22.05% and a net margin of 28.14%. The company had revenue of $907.00 million during the quarter, compared to analyst estimates of $872.65 million. During the same period in the prior year, the firm posted $1.52 earnings per share. The firm’s revenue was up 6.3% on a year-over-year basis. On average, equities analysts anticipate that Illumina, Inc. will post 6.44 EPS for the current fiscal year.
A number of equities research analysts have weighed in on ILMN shares. Piper Jaffray Companies reduced their price objective on Illumina from $348.00 to $341.00 and set an “overweight” rating for the company in a research note on Friday, October 25th. UBS Group boosted their price objective on Illumina from $350.00 to $355.00 and gave the company a “buy” rating in a research note on Tuesday, July 30th. Canaccord Genuity boosted their price objective on Illumina from $300.00 to $310.00 and gave the company a “hold” rating in a research note on Friday, October 25th. BidaskClub cut Illumina from a “buy” rating to a “hold” rating in a research note on Saturday. Finally, Cowen set a $320.00 price objective on Illumina and gave the company a “buy” rating in a research note on Friday, October 25th. One investment analyst has rated the stock with a sell rating, five have given a hold rating and ten have issued a buy rating to the company’s stock. Illumina presently has an average rating of “Buy” and a consensus price target of $333.38.
Illumina, Inc provides sequencing and array-based solutions for genetic analysis. The company operates in two segments, Core Illumina and Consolidated VIEs. It offers sequencing that provides researchers with various applications and the ability to sequence mammalian genomes; and arrays for a range of deoxyribonucleic acid and RNA analysis applications, including single nucleotide polymorphism genotyping, copy number variations analysis, gene expression analysis, and methylation analysis, as well as enables the detection of known genetic markers on a single array.
Recommended Story: Terms to Better Understand Call Options
Want to see what other hedge funds are holding ILMN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Illumina, Inc. (NASDAQ:ILMN).
Receive News & Ratings for Illumina Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina and related companies with MarketBeat.com's FREE daily email newsletter.